Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation...

Area of Science:

• Global Health
• Pharmaceutical Industry
• Public Health Policy

Background:

• Growing demand for public accountability and transparency in private sector-led global health initiatives.
• Need for standardized frameworks to assess and report on the performance of these programs.

Purpose of the Study:

• To critically review and pilot test the World Health Organization (WHO) medicine program checklist.
• To evaluate its utility as a framework for public reporting and program assessment.

Main Methods:

• Systematic review of WHO checklist questions for clarity and usability.
• Pilot testing of checklist questions focused on program assessment.
• Analysis of publicly available data from 20 biopharmaceutical companies' global health programs.

Main Results:

• Checklist questions cover national health plans, financial/performance accountability, risk management, and sustainability.
• Companies frequently report on public health needs (100%), objectives (100%), and outputs (95%).
• Significant gaps exist in reporting on country plan alignment (50%), M&E plans (20%), risk mitigation (5%), and government resource contributions (0%).

Conclusions:

• The WHO checklist is a potentially valuable tool for public reporting of medicine access programs.
• Most questions require data readily available from program leaders.
• Further revisions are needed to enhance clarity and content validity for improved public accountability.